Trials / Unknown
UnknownNCT05338957
A Study of MRG002 in the Treatment of Patients With HER2-expressed Advanced Malignant Solid Tumors.
An Open-label, Multi-center, Phase I/II Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of MRG002 in Combination With HX008 in Patients With HER2-expressed Advanced Malignant Solid Tumors.
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Shanghai Miracogen Inc. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to assess the safety and tolerability of MRG002 in combination with HX008 in patients with HER2-expressed advanced malignant solid tumors; and to , explore the maximum tolerated dose (MTD), and to determine the recommended phase II dose (RP2D) of combination therapy; , and to evaluate the preliminary efficacy, pharmacokinetics, and immunogenicity of combination therapy in the targeted study population.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MRG002+HX008 | Administrated intravenously |
Timeline
- Start date
- 2022-08-05
- Primary completion
- 2024-06-01
- Completion
- 2024-12-01
- First posted
- 2022-04-21
- Last updated
- 2022-12-01
Locations
5 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05338957. Inclusion in this directory is not an endorsement.